Development and testing of in vitro companion assay for novel hypoxia-activated mitochondrial prodrugs****

点击翻译按钮获取中文摘要

Cyclica has developed a new technology, termed Differential Drug Discovery (DDD), to design single molecules capable of targeting multiple proteins simultaneously and retain drug like characteristics. The project will design tumour specific pro-drugs to target mitochondrial respiration. To achieve this Cyclica software developers must design constructs to predict chemical structures that will target various proteins in the mitochondria. Our team will develop a companion assay to test the novel chemical structures designed in the software and substantiate the computer aided predictions. We will perform optimization, benchmarking and assays required for Cyclica to proceed to the commercialization of the novel computational drug discovery application of their AI technology.**